EG 427 Announces Compelling Initial Topline Clinical Results with EG110A DNA Medicine in Neurogenic Bladder Patients
October 02, 2025- Over 88% reduction in urinary incontinence episodes achieved in low dose cohort at 12 weeks
- Good tolerability with no systemic side effects
- First DNA medicine to selectively target, at the local level, a specific subtype of sensory neurons
- Fully validates mechanism targeting type-C sensory neurons, opening the door to a broad range of other neurological indications
- Results validate EG 427’s proprietary HERMES nrHSV-1 technology platform
Read the full press release in English or in French